Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620566 | 0.91 | PIK3CA (0.42) | HDAC1PIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL100419 | 0.90 | TP53 (0.42) | HDAC1PIK3CAPIK3CDALDH1A1LMNA | |
| SCHEMBL1620568 | 0.86 | HDAC1 (0.38) | HDAC1PIK3CAPIK3CDPIK3CBLMNA | |
| SCHEMBL16556630 | 0.85 | HDAC1 (0.43) | HDAC1PIK3CAPIK3CDPIK3CBRGS12 | |
| SCHEMBL97685 | 0.84 | PIK3CA (0.51) | HDAC1PIK3CAPIK3CDPIK3CBKDM4E | |
| SCHEMBL99008 | 0.84 | PIK3CA (0.46) | HDAC1PIK3CAPIK3CDPIK3CBKDM4E | |
| SCHEMBL98839 | 0.83 | MAPT (0.43) | HDAC1PIK3CAPIK3CDALDH1A1LMNA | |
| SCHEMBL97899 | 0.83 | MAPT (0.45) | HDAC1PIK3CAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL97732 | 0.82 | PIK3CA (0.53) | HDAC1PIK3CAPIK3CDPIK3CBKDM4E | |
| SCHEMBL99288 | 0.82 | GAA (0.42) | HDAC1PIK3CAPIK3CDPIK3CBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | HDAC1 3179/4885PIK3CA 1539/4885PIK3CD 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.